related_research

Join a Supportive Care Trial

Quality of Life Trials or Supportive Care Trials are research studies to evaluate improving the health, care or quality of life for people, typically without using study drugs or devices. UCSF's Memory and Aging Center (MAC) runs selected supportive trials for people with neurodegenerative disease. Your participation helps us evaluate these interventions. If one of our trials looks interesting to you, please talk with your doctor or contact the study team to see if it is appropriate for you.

Cerebrovascular & Parkinson’s Disease Videogame Study

The goal of this study is to determine the efficacy of a tablet-based videogame (EVO) on cognition in non-demented patients with Parkinson’s disease (PD) or cerebrovascular disease.

Participants with Parkinson’s disease who want to volunteer for research on Parkinson’s disease should first join the Parkinson’s Disease Eligibility & Screening Visit. Participating in the eligibility and screening visit involves a single visit to the UCSF Memory and Aging Center and will enable you to potentially get involved in other studies in the Bay Area.

Summary

Emotion in Parkinson’s Disease

The goal of this study is to learn how Parkinson’s disease affects social and emotional behavior. For example, we aim to assess how participants respond to different kinds of emotional stimuli and whether they can recognize emotions in other people. In addition, we study the emotional behavior of caregivers and their experience of caring for a loved one with Parkinson’s disease.

Participants with Parkinson’s disease who want to volunteer for research on Parkinson’s disease should first join the Parkinson’s Disease Eligibility & Screening Visit. Participating in the eligibility and screening visit involves a single visit to the UCSF Memory and Aging Center and will enable you to potentially get involved in other studies in the Bay Area.

Summary

Molecular Imaging in Parkinson’s Disease

The goal of this study is to learn more about the levels of tau and amyloid proteins in brains of people who have Parkinson’s disease.

Participants with Parkinson’s disease who want to volunteer for research on Parkinson’s disease should first join the Parkinson’s Disease Eligibility & Screening Visit. Participating in the eligibility and screening visit involves a single visit to the UCSF Memory and Aging Center and will enable you to potentially get involved in other studies in the Bay Area.

Summary

Parkinson’s Disease Eligibility & Screening Visit

The Memory and Aging Center is currently recruiting participants with Parkinson’s disease (PD) for involvement in several different research projects at UC San Francisco and UC Berkeley.

Summary

  • Study director: Joel Kramer, PsyD
  • Sponsor: National Institutes of Health (NIH)
  • Recruiting?: Yes
  • Official study title: Parkinson’s Disease Eligibility and Screening
  • Conditions studied: Parkinson's disease (PD)

Purpose of Study

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

The goal of this study is to support the development of FTLD therapies through a multi-site research consortium headquartered at UCSF. The study aims to determine the clinical, genetic, and biomarker profiles of FTLD syndromes where there is a strong correlation between clinical syndrome and underlying pathology (FTD-ALS, PSP, and semantic variant PPA (svPPA)). The study also aims to determine the natural history of familial FTLD using novel clinical measures.

Summary

  • Study directors: Adam Boxer, MD, PhD and Howard Rosen, MD
  • Sponsor: National Institutes of Health (NIH)
  • Recruiting?: Yes
  • Official study title: Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

Progressive Supranuclear Palsy Trial of Oral Salsalate

Salsalate has been marketed for decades in the US as a prescription drug for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and related rheumatic disorders, but this is the first time salsalate will be studied in people with PSP. The purpose of this study is to determine the safety and tolerability of oral salsalate in people with PSP.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Funder: Tau Consortium
  • Recruiting?: Yes
  • Official study title: A 6-Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy
  • ClinicalTrials.gov identifier: NCT02422485

Progressive Supranuclear Palsy Trial of Plasma Transfusions

Young healthy male donor plasma is commonly used to correct clotting deficiencies, but this is the first time it will be studied in people with PSP. The purpose of this study is to determine the safety and tolerability of donor plasma transfusions in patients with PSP.

Summary

  • Study director: Richard Tsai, MD, MBA
  • Funder: Tau Consortium
  • Recruiting?: Yes
  • Official study title: A 6-Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy

Frontotemporal Dementia with Granulin Mutation Trial of a Histone Deacetylase Inhibitor

The aim of this trial is to evaluate the safety and tolerability of FRM-0334 in subjects with prodromal to moderate frontotemporal dementia with granulin mutation and to see if it causes a change in plasma concentrations of progranulin.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: FORUM Pharmaceuticals
  • Recruiting?: Yes
  • Official study title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation

Huntington’s Disease Trial of Laquinimod (LEGATO-HD)

The purpose of this study is to evaluate the efficacy, safety, and tolerability of laquinimod which is hypothesized to decrease inflammatory processes that occur in the brain in Huntington’s disease.

Summary

  • Study director: Michael Geschwind, MD, PhD
  • Sponsor: Teva Branded Pharmaceutical Products R&D, Inc
  • Recruiting?: February 2015
  • Official study title: A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease
Syndicate content